Acadia Healthcare (NASDAQ:ACHC – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Risk & Volatility
Acadia Healthcare has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Acadia Healthcare and Mangoceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acadia Healthcare | 2 | 5 | 7 | 1 | 2.47 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
Earnings and Valuation
This table compares Acadia Healthcare and Mangoceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acadia Healthcare | $3.31 billion | 0.79 | -$1.10 billion | ($12.45) | -2.26 |
| Mangoceuticals | $460,000.00 | 21.21 | -$20.64 million | ($1.01) | -0.45 |
Mangoceuticals has lower revenue, but higher earnings than Acadia Healthcare. Acadia Healthcare is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. 1.2% of Acadia Healthcare shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Acadia Healthcare and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acadia Healthcare | -33.44% | 6.19% | 2.42% |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
Summary
Acadia Healthcare beats Mangoceuticals on 8 of the 15 factors compared between the two stocks.
About Acadia Healthcare
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
